B细胞型幼淋巴细胞白血病1例并文献复习

《现代肿瘤医学》[ISSN:1672-4992/CN:61-1415/R] 期数: 2019年08期 **页码:** 1400-1402 **栏目:** 论著（造血器·淋巴系肿瘤） **出版日期:** 2019-03-08

Title: B-cell lymphocytic leukemia：One case report and literature review

作者: 夏 思; 古学奎
广州中医药大学第一临床医学院，广东 广州 510405

Author(s): Xia Si; Gu Xuekui
The First Clinical Medical College of Guangzhou University of Chinese Medicine，Guangdong Guangzhou 510405，China.

关键词: B细胞型幼淋巴细胞白血病; B细胞淋巴瘤; 免疫组化分型

Keywords: B-cell lymphocytic leukemia; B-cell lymphoma; immunophenotyping

分类号: R733.7

DOI: 10.3969/j.issn.1672-4992.2019.08.027

文献标识码: A

摘要: 目的:提高对B细胞型幼淋巴细胞白血病（B-PLL）的诊治认识。方法：回顾分析了我院1例B-PLL患者的临床表现、骨髓细胞形态学、免疫分型、不良基因检测等临床资料以及治疗过程,并结合文献进行学习讨论。结果：B-PLL患者初诊时白细胞总数较高,脾肿大；骨髓形态学呈体积中等的幼稚淋巴细胞，核圆、核仁清晰、核染色质浓密、核浆比例低的特点；成熟B细胞免疫表型，免疫球蛋白轻链限制性表达，排除其他淋巴增殖性疾病，诊断为B细胞型幼淋巴细胞白血病。该患者TP53缺失，给予R-CHOP方案治疗，治疗反应差。结论：形态学检查和免疫表型是诊断B-PLL的重要手段，同时需整合临床表现、细胞遗传学等结果综合判断，TP53基因缺失或突变会导致这类患者传统化疗的预后不良。

Abstract: Objective:To improve the diagnosis and treatment of B-cell lymphocytic leukemia (B-PLL).Methods:The clinical features,morphology,immunophenotyping,genetic testing and treatment of one case of B-PLL patients in our hospital were retrospectively analyzed,and the related literatures were reviewed. Results:B-PLL patients had a higher count of white blood cells and massive splenomegaly at the initial diagnosis.The bone marrow morphology is characterized by immature lymphocytes of medium volume which has a round and prominent central nucleolus with condensed chromatin and decreased nuclear to pulp ratio.Combining with mature B cell immune phenotype,restricted expression of immunoglobulin light chain,it was finally diagnosed as B-cell lymphoblastic leukemia while excluding other lymphoid proliferation.The patient was deficient in TP53 and treated with r-chop regimen whose response was poor.Conclusion:The morphology and the immune phenotype is an important methods for the diagnosis of B-PLL,but need to integrate the results of clinical manifestations,cytogenetics,and other comprehensive judgments.Deletion or mutation of the TP53 gene may result in poor prognosis of conventional chemotherapy in these patients.

参考文献/REFERENCES

[1] Tian Yuan,Liu Hui.Management of prolymphocytic leukemia-A tipsheet of 57th America hematology conference (ASH) in 2015 [J] .Clinical Medication Journal,2016,14 (5) : 13-14. [田园，刘辉.幼淋巴细胞白血病的治疗进展-2015年第57届美国血液学年会（ASH） [J] .临床药物治疗杂志，2016,14 (5) : 13-14.]
[2] Dearden C.How I treat prolymphocytic leukemia [J] .Blood,2012,120(3):538-551.
[3] Sabattini E,Bacci F,Sagramoso C,et al.WHO classification of tumours of haematopoietic and lymphoid tissues in 2008:an overview [M] .International Agency for Research on Cancer,2008:83-87.
[4] Swerdlow SH,Campo E,Pileri SA,et al.The 2016 revision of the World Health Organization (WHO) classification of lymphoid neoplasms [J] .Blood,2016,127(20):2375.
[5] Hematology Branch of Chinese Medical Association.Expert consensus on diagnosis of B cell chronic lymphoproligerative disorders in China (2014) [J] .Chinese Journal of Hematology,2014,35(4):367-370. [中华医学会血液学分会.中国B细胞慢性淋巴增殖性疾病诊断专家共识(2014年版) [J] .中华血液学杂志,2014,35(4):367-370.]

[6] Collignon Aude,Wanquet Anne,Maitre Elsa,et al.Prolymphocytic leukemia:New insights in diagnosis and in treatment [J] .Current Oncology Reports,2017,11(29):2-5.
[7] Lens D,De Schouwer PJ,Hamoudi RA,et al.p53 abnormalities in B-cell prolymphocytic leukemia [J] .Blood,1997,89(6):2015-2023.
[8] Lens D,Matutes E,Catovsky D,et al.Frequent deletions at 11q23 and 13q14 in B cell prolymphocytic leukemia (B-PLL) [J] .Leukemia,2000,14(3):427-430.
[9] Flatley E,Chen AI,Zhao X,et al.Aberrations of MYC are a common event in B-cell prolymphocytic leukemia [J] .American Journal of Clinical Pathology,2014,142(3):347-354.
[10] Van der Velden VH,Hoogeveen PG,deRidder D,et al.B-cell prolymphocytic leukemia:a specific subgroup of mantle cell lymphoma [J] .Blood,2014,124(3):412-419.
[11] Treon SP,Xu L,Yang G,et al.MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia [J] .New England Journal of Medicine,2012,367(9):826.
[12] Xu L, Hunter ZR, Yang G,et al.MYD88 L265P in waldenstrom's macroglobulinemia,IgM monoclonal gammopamy,and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific PCR [J] .Blood, 2013, 121(11): 2051-2058.
[13] Vito Franco, Ada Maria Florena,Emilio Iannitto.Splenic marginal zone lymphoma [J] .Blood,2003,101:2464-2472.
[14] Dohner H,Ho AD,Thaler J,et al.Pentostatin in prolymphocytic leukemia:phase II trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study Group [J] .Journal of the National Cancer Institute,1993,85(8):658-662.
[15] Saven A,Lee T,Schlutz M,et al.Major activity of cladribine in patients with de novo B-cell prolymphocytic leukemia [J] .Journal of Clinical Oncology,1997,15(1):37-43.
[16] Mourad YA,Taher A,Chehal A,et al.Successful treatment of B-cell prolymphocytic leukemia with monoclonal anti-CD20 antibody [J] .Annals of Hematology,2004,83(5):319-321.
[17] Perz J,Topaly J,Fruehauf S,et al.Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia [J] .Leukemia & Lymphoma,2002,43(1):149-151.
[18] Dearden C.Management of prolymphocytic leukemia [J] .Hematology,2015,2015(1):361-367.
[19] Melo T,Badior M,Coelho H.Sequential Kinase inhibition (Idelalisib/Ibrutinib) induces clinical remission in B-cell prolymphocytic leukemia harboring a 17p deletion [J] .Case Reports in Hematology,2017,2017(12):1-4.
[20] Kai UC,Kim SZ,Neuhoff NV,et al.Clinical efficacy of immunochemotherapy with fludarabine,epirubicin and rituximab in the treatment for chronic lymphocytic leukemia and prolymphocytic leukemia [J] .European Journal of Hematology,2011,87(5):426-433.
[21] Tempescul A,Feuerbach J,Ianotto JC,et al.A combination therapy with fludarabine,mitoxantrone and rituximab induces complete immunophenotypical remission in B-cell prolymphocytic leukemia [J] .Annals of Hematology,2009,88(1):85-88.
[22] Bowen AL,Zomas A,Emmett E,et al.Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukemia [J] .British Journal of Hematology,1997,96(3):617.
[23] Chaar BT,Petruska PJ.Complete response to alemtuzumab in a patient with B prolymphocytic leukemia [J] .American Journal of Hematology,2007,82(5):417.
[24] Gordon MJ,Raess PW,Young K,et al.Ibrutinib is an effective treatment for B-cell prolymphocytic leukemia [J] .British Journal of Hematology,2017,179(3):501.
[25] Eyre TA,Fox CP,Shankara P,et al.Idelalisib-Rituximab induces clinical remissions in patients with TP53 disrupted B cell prolymphocytic leukemia [J] .British Journal of Hematology,2017,177(3):486.

备注/Memo: -

更新日期/Last Update: 1900-01-01